Roche discontinues SMA candidate

Roche (SIX:ROG; OTCQX:RHHBY) said it will discontinue development of spinal muscular atrophy candidate olesoxime (RG6083, TRO19622). In April, Roche presented data at the American Academy of Neurology meeting in Los Angeles from the long-term follow-up OLEOS study showing that the candidate led to a worsening in motor function.

The pharma also cited in its reasoning difficulties in formulating olesoxime and identifying an appropriate dose, as well as changes in the SMA treatment landscape...